We identify the SLC22A3-LPAL2-LPA gene cluster as a strong susceptibility locus for coronary artery disease (CAD) through a genome-wide haplotype association (GWHA) study. This locus was not identified from previous genome-wide association (GWA) studies focused on univariate analyses of SNPs. The proposed approach may have wide utility for analyzing GWA data for other complex traits.
Our analysis comprised three stages. In the first stage, the Wellcome Trust Case Control Consortium (WTCCC) CAD study, composed of 1,926 CAD cases and 2,938 controls genotyped with the Affymetrix 500K chip 1, 2 , was used to identify regions with suggestive evidence of haplotype association using a sliding-windows approach (Supplementary Methods online). The analysis was carried out using the European EGEE grid 3 of computers. We searched for regions fulfilling two a priori defined criteria: (i) a haplotype-based P value lower than 10 À5 and (ii) a haplotype-based P value at least 100 times smaller than the smallest single-SNP P value observed in the corresponding region. We fixed the first criterion at a threshold that was not too stringent, in order to increase the sensitivity of the analysis given the higher number of degrees of freedom of haplotype tests as compared to single-SNP tests. The second criterion was applied to identify new susceptibility regions where haplotypes are more informative than single SNPs to predict disease status. Using these criteria, we identified 29 regions (involving 94 SNPs) in the WTCCC data (Supplementary Table 1 online).
In the second stage, we investigated these regions in the GWA data of the German Myocardial Infarction Family Study I (GerMIFS I) 1 , composed of 875 CAD cases and 1,644 controls typed with the same Affymetrix array. Because of the lower performance of the algorithm used for calling GerMIFS I genotypes 1 , 24 of the 94 SNPs did not pass the quality control and the 21 regions involving these SNPs were not further analyzed. We confirmed the high validity of the remaining genotypes that were called in the GerMIFS I study by comparing the genotypes obtained on the GWA platform for a proportion of the SNPs with those obtained with an alternate platform (Supplementary Methods). Of the eight regions where exact haplotype replication analysis could be undertaken, one showed strong evidence for association (P ¼ 3.70 Â 10 À4 after Bonferroni correction for the number of tested regions). This region includes four SNPs overlapping the SLC22A3-LPAL2-LPA gene cluster on chromosome 6q26-q27 (see Supplementary Fig. 1 online for their pattern of linkage disequilibrium). The frequency distribution of the haplotypes derived from these four SNPs was consistently and significantly different between cases and controls of the WTCCC and the GerMIFS I studies ( Table 1) .
In a third stage, we investigated the association of the haplotypes derived from these four SNPs (rs2048327 in the SLC22A3 gene, rs3127599 in the LPAL2 gene and rs7767084 and rs10755578 in the LPA gene) with CAD in four additional studies composed of 1,222 CAD cases and 1,298 controls (GerMIFS II) 4,5 , 1,679 CAD cases and 1,524 controls (Angio-Luebeck study), 2,199 CAD cases and 1,809 controls (PopGen) 6 and 1,098 myocardial infarction cases and 1,050 controls (ECTIM) 7 (Supplementary Methods). A population-adjusted combined analysis of these four studies provided strong support (P ¼ 1.23 Â 10 À9 ) for haplotype association at the 6q26-q27 locus.
In the six studies, the same seven common (frequency 40.01) haplotypes were inferred from the four SNPs (Table 1) . In a combined individual-level analysis of the six datasets totaling 8,999 cases and 10,263 controls, the overall evidence for global haplotypic association adjusted for study was strong (P ¼ 1.34 Â 10 À21 ). The association was mainly attributable to two haplotypes (CTTG and CCTC) whose frequency was increased in cases compared to controls (Fig. 1) . The CTTG haplotype was associated with a combined odds ratio (OR) of 1.202 (95% CI ¼ 1.133-1.275, P ¼ 1.19 Â 10 À9 ) when compared to the most frequent TCTC haplotype, with no evidence for heterogeneity across the six studies (P ¼ 0.826). The less frequent CCTC haplotype was associated with a combined OR of 1.822 (95% CI ¼ 1.568-2.116, P ¼ 4.20 Â 10 À15 , P for heterogeneity ¼ 0.532; Fig. 1 ). These two haplotypes both carry the rs2048327[C] allele, which was also strongly associated with an increased risk in the combined samples (P ¼ 3.98 Â 10 À13 , Supplementary Table 2 online). We therefore tested whether the association with CAD in all datasets combined might be compatible with the sole effect of the rs20848327[C] allele, but this hypothesis was rejected (P ¼ 3.14 Â 10 À11 , Supplementary Table 2) . We also examined whether the association observed could be explained by untyped SNP(s) located close to those that had been genotyped. Genotypes for up to 2.5 million SNPs have been imputed from the WTCCC data 8 . No single imputed SNP at this locus showed stronger evidence of association with CAD than the haplotypes identified by the sliding-window approach ( Supplementary Fig. 2 online) .
The identified locus partly overlaps the LPA gene, which encodes apolipoprotein(a), the main protein of lipoprotein(a) (Lp(a)), a known risk factor for CAD 9,10 whose plasma measurements were available in the ECTIM study 9 . We therefore examined the association of the identified haplotypes with Lp(a) levels in ECTIM. The haplotypes associated with CAD were those associated with the highest Lp(a) levels, and after adjustment for Lp(a) levels, these were no longer associated with myocardial infarction (P ¼ 0.102), suggesting that their relation to risk is mediated by an effect on Lp(a). Lp(a) levels are strongly heritable and the LPA locus accounts for almost the whole heritability 11 . A kringle-repeat polymorphism of the LPA gene is known to be the key determinant of Lp(a) levels. In ECTIM, 34% of Lp(a) variability was attributable to this repeat polymorphism, but an additional fraction of 15% (P ¼ 6.02 Â 10 À20 ) was explained by the haplotypes combining the four SNPs of the present analysis and a LPA The WTCCC Study was the primary study where GWHA was done (stage 1). This was followed by replication in the GerMIFS I GWA data (stage 2) and follow-up replication in the other four studies (stage 3).
promoter SNP, rs1800769, which was genotyped in ECTIM 9 but not characterized by HapMap data and not available in the studies analyzed using the DNA arrays (Supplementary Methods and Supplementary Fig. 2) . Notably, the rs1800769 SNP splits the CTTG haplotype into two subhaplotypes, and only one of them is associated with increased Lp(a) levels ( Supplementary Fig. 3 online) and increased risk of CAD (Supplementary Table 3 online).
To our knowledge, this work is the first to report results from a genome-wide haplotype analysis with replication of the findings. A recent study 12 carried out a haplotype analysis of the WTCCC data for seven diseases investigated in that project but did not detect any new CAD susceptibility locus. The statistical methodology used by these authors for detecting haplotype effects was different from ours in several aspects; in particular, they used a lower number of investigated haplotypic configurations (1.5 million versus 8.1 million in our study) and a different statistical methodology for testing association (Supplementary Methods). Moreover, these investigators did not include any replication study.
The genome-wide haplotype strategy identified the chromosome 6q26-q27 locus as a strong susceptibility locus for CAD. This locus encompasses the SLC22A3, LPAL2 and LPA genes, the latter having a long history of suggestive association with CAD 13 . Further work is necessary to determine whether the detected haplotype effects are the reflection of interactions between SNPs at the haplotypic level or whether they are tagging ungenotyped functional variants. The LPA gene shows a highly complex pattern of variability, with several copy number variations (CNV) polymorphisms not well characterized by the DNA arrays used. This might explain why this locus was not suspected from our previous GWA studies 1 based on single-SNP analyses and was not detected through imputed data analysis. As one of the detected haplotypes was relatively uncommon and associated with strong genetic effect, our work raises the possibility that haplotypes based on common SNPs may identify relatively rare variants of clinical interest.
Both the completeness and the fidelity of the genotyping have a more significant impact on GWHA than on single-SNP GWA analysis, especially when comparisons across studies is planned. This is highlighted by the number of loci that we were unable to compare between the WTCCC and GerMIFS I GWA data. Furthermore, the much larger number of association tests undertaken, which are not all independent, means that conventional thresholds used in single-SNP GWA analysis to indicate genome-wide significance cannot be easily translated to GWHA and a robust replication strategy is necessary, regardless of what thresholds are used to identify regions for followup. Because of these issues, we cannot exclude the possibility that other haplotype-based loci associated with risk of CAD were missed in the present analysis. Nonetheless, our results illustrate the utility of GWHA analysis of genotype data obtained on currently available GWA platforms to identify new susceptibility loci for complex human diseases.
Note: Supplementary information is available on the Nature Genetics website. Figure 1 Haplotypic odds ratios (ORs) for CAD associated with the CCTC and CTTG haplotypes derived from rs2048327, rs3127599, rs7767084 and rs10755578 on chromosome 6q26-q27. Squares, with size proportional to the size of the study sample, represent ORs with their 95% confidence interval. These are haplotypic ORs by comparison to the most frequent TCTC haplotype, under the assumption of haplotypic additive effects. We estimated ORs from a combined analysis of all individual datasets while adjusting for study and after having checked for the homogeneity using the Mantel-Haenszel method.
